Literature DB >> 12432041

Dexamethasone in adults with bacterial meningitis.

Jan de Gans1, Diederik van de Beek.   

Abstract

BACKGROUND: Mortality and morbidity rates are high among adults with acute bacterial meningitis, especially those with pneumococcal meningitis. In studies of bacterial meningitis in animals, adjuvant treatment with corticosteroids has beneficial effects.
METHODS: We conducted a prospective, randomized, double-blind, multicenter trial of adjuvant treatment with dexamethasone, as compared with placebo, in adults with acute bacterial meningitis. Dexamethasone (10 mg) or placebo was administered 15 to 20 minutes before or with the first dose of antibiotic and was given every 6 hours for four days. The primary outcome measure was the score on the Glasgow Outcome Scale at eight weeks (a score of 5, indicating a favorable outcome, vs. a score of 1 to 4, indicating an unfavorable outcome). A subgroup analysis according to the causative organism was performed. Analyses were performed on an intention-to-treat basis.
RESULTS: A total of 301 patients were randomly assigned to a treatment group: 157 to the dexamethasone group and 144 to the placebo group. The base-line characteristics of the two groups were similar. Treatment with dexamethasone was associated with a reduction in the risk of an unfavorable outcome (relative risk, 0.59; 95 percent confidence interval, 0.37 to 0.94; P=0.03). Treatment with dexamethasone was also associated with a reduction in mortality (relative risk of death, 0.48; 95 percent confidence interval, 0.24 to 0.96; P=0.04). Among the patients with pneumococcal meningitis, there were unfavorable outcomes in 26 percent of the dexamethasone group, as compared with 52 percent of the placebo group (relative risk, 0.50; 95 percent confidence interval, 0.30 to 0.83; P=0.006). Gastrointestinal bleeding occurred in two patients in the dexamethasone group and in five patients in the placebo group.
CONCLUSIONS: Early treatment with dexamethasone improves the outcome in adults with acute bacterial meningitis and does not increase the risk of gastrointestinal bleeding. Copyright 2002 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432041     DOI: 10.1056/NEJMoa021334

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  249 in total

Review 1.  Bacterial meningitis: diagnosis and treatment.

Authors:  Russell D Snyder
Journal:  Curr Neurol Neurosci Rep       Date:  2003-11       Impact factor: 5.081

Review 2.  Acute bacterial meningitis: time for a better outcome.

Authors:  Werner Zimmerli
Journal:  Intensive Care Med       Date:  2003-11       Impact factor: 17.440

3.  Management of bacterial meningitis in adults.

Authors:  Jonathan Cohen
Journal:  BMJ       Date:  2003-05-10

4.  Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid.

Authors:  Wolfgang A Krueger; Bernd Kottler; Bernd E Will; Alexandra Heininger; Heinz Guggenberger; Klaus E Unertl
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 5.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  Treatment difficulties of a listerial rhombencephalitis in an adult patient allergic to penicillins.

Authors:  G A Popescu; M Saquepée; D Poisson; T Prazuck
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

Review 7.  Difficult and recurrent meningitis.

Authors:  L Ginsberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

Review 8.  Neuro-intensive care of patients with acute CNS infections.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

9.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

10.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.